This event is not a part of the official program of FMX.
Tuesday, October 7, 2025
5:45 AM – 6:00 AM PT Registration & Breakfast
6:00 AM – 7:30 AM PT CE Symposium
The Westin Anaheim Resort
1030 West Katella Avenue
Anaheim, CA 92802
PROGRAM FEATURES
- Interactive case-based presentation
- Downloadable whiteboard animation
- Online personalized quality-improvement poster-generation portal
PRESENTING FACULTY
 |
Matthew T. Rosenberg, MD Managing Partner Mid-Michigan Health Centers Jackson, Michigan |
PROGRAM OVERVIEW
This innovative satellite symposium presents the diagnostic criteria for benign prostatic hyperplasia (BPH) and overactive bladder (OAB), highlighting essential characteristics, differential diagnoses, screening tools, and testing methods, as well as guidelines for when a referral to urology is necessary. It also assesses clinical data and current guidelines regarding both established and emerging treatment options for BPH and OAB. Furthermore, the symposium emphasizes the importance of shared decision-making (SDM) and multidisciplinary team (MDT) approaches to tailoring treatment plans, enhancing patient adherence, and effectively managing comorbidities and adverse events.
LEARNING OBJECTIVES:
- Describe the diagnostic criteria for BPH and OAB, including key features, differential diagnoses, screening tools, testing methods, and clinical scenarios warranting urology referral.
- Evaluate clinical data and guideline recommendations for current and emerging treatments for BPH and OAB and best practices for routine treatment monitoring.
- Utilize SDM and MDT approaches to individualize treatment, improve adherence, and appropriately manage comorbidities and AEs.
TARGET AUDIENCE
This activity is intended for primary care physicians involved in the management of patients with benign prostatic hyperplasia (BPH) and overactive bladder syndrome (OAB).
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.50 ANCC contact hours.
AAFP CREDIT
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at [email protected]
